Argus analyst David Toung lowered the price target on Stryker (NYSE: SYK) to $350.00 (from $435.00) while maintaining a Buy rating.

The analyst comments "Reaffirms 2026 guidance despite cyberattack • A cyberattack disrupted operations and hurt revenue and EPS growth in 1Q26, but Stryker management highlighted the strength of its business execution and underlying customer demand in generating strong topline growth in the second half of 2026. • The acquisitions of Inari Medical and Amplitude Vascular Systems strengthen Stryker's presence in the field of peripheral vascular surgery and intervention. • In light of market volatility, we are lowering our price target to $350 from $435."